Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)

Launched by ASSIUT UNIVERSITY · Oct 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in the staging system for endometrial cancer—specifically, the shift from the FIGO 2009 system to the updated FIGO 2023 system—affect how doctors understand the severity of the disease and make treatment decisions. The study aims to see how these new guidelines might change the stage of cancer for patients, how this impacts their chances of survival, and how it influences the additional treatments they might receive after surgery.

To participate in this trial, women aged 65 to 74 who have been diagnosed with endometrial cancer and have undergone specific surgical procedures between January 2018 and December 2022 may be eligible. Participants should have their medical records and follow-up information for at least two years after their diagnosis. They will not be included if they had certain prior treatments or other health issues. If you join the study, you can expect to contribute to important research that could help improve treatment plans for future patients with endometrial cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Patients diagnosed with endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) between January 1, 2018, and December 31, 2022 with available medical records since diagnosis and at least follow up 2 years and received adjuvant treatment and available histopathological slides and blocks.
• Exclusion Criteria:
• • - Patients who received neoadjuvant chemotherapy, had recurrent endometrial cancer, had multiple cancers, lacked histopathological slides and formalin-fixed paraffin-embedded blocks or lacked medical records were excluded